press release

May 5, 2017

- Patisiran Demonstrates Continued Evidence for Potential Halting of Neuropathy Progression and First Ever Results Showing Statistically Significant Improvement in Nerve Fiber Density in Patients with Familial Amyloidotic Polyneuropathy (FAP) Patisiran APOLLO Trial on Track to Complete Enrollment in Next 3 4 Months; if Positive, Expect New Drug Application (NDA) Filing in 2017 Revusiran Demonstrates Robust and ...

press release

May 5, 2017

- Provides Opportunity for People with Hemophilia who Participated in Phase 1 Trial to Receive ALN AT3 on Ongoing Basis Pivotal Studies on Track to Begin in Mid 2016 CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 open label extension ...

press release

May 5, 2017

- Advanced Late Stage Clinical Pipeline: Patisiran APOLLO Phase 3 Trial on Track to Complete Enrollment in Next 3 4 Months; if Positive, Expect NDA Filing in 2017 Presented Positive Clinical Data for ALN PCSsc for Hypercholesterolemia and ALN AS1 for Acute Hepatic Porphyrias Maintained Strong Balance Sheet with $1.34 Billion in Cash and Expect to End ...

press release

May 5, 2017

-Marks First Product Opt In since Formation of Landmark 2014 Alliance for Global Advancement of RNAi Therapeutics as Genetic Medicines CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), today announced that Genzyme has elected to opt into Alnylam's investigational ALN ...

press release

May 5, 2017

- In Phase 1 Study of Asymptomatic High Excreter (ASHE) Patients with Acute Intermittent Porphyria (AIP), ALN AS1 Achieves up to 82% Lowering of Aminolevulinic Acid (ALA) and up to 93% Lowering of Porphobilinogen (PBG), the Toxic Heme Synthesis Intermediates that Mediate Porphyria Attacks Using Exosomal mRNA Preparations from Serum and Urine, ALN AS1 Showed Potent, ...

press release

May 5, 2017

- Company Expects to Present Initial Clinical Results in Early 2016 CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase 1/2 clinical trial with ALN AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha 1 antitrypsin (AAT) for the treatment of AAT ...

press release

May 5, 2017

- Advanced Pipeline of Seven Investigational Clinical Programs and Presented Positive Clinical Results for Three: Patisiran for Familial Amyloidotic Polyneuropathy (FAP), ALN AT3 for Hemophilia, and ALN CC5 for Complement Mediated Diseases In Addition to Upcoming Presentation of ALN PCSsc Clinical Results, Announces New Plan to Present Initial Clinical Data for ALN AS1 Porphyria Program at ...

press release

May 5, 2017

- Investigational First in Class PCSK9 Synthesis Inhibitor Achieves up to 83% Maximal and 64% Mean Maximum LDL C Lowering, Comparable to Published Results with Anti PCSK9 Monoclonal Antibodies, but with Clinically Significant Reductions in LDL C Clamped Down for More than 140 Days after Just a Single Dose ALN PCSsc Generally Well Tolerated with No Clinically ...

press release

May 5, 2017

- Patisiran, an Intravenously Administered Investigational RNAi Therapeutic Targeting TTR, Achieves an Approximately 90% Reduction in Misfolded Non Native Conformations of TTR (NNTTR) as Measured in Serum In Addition, Complete 12 Month Data (N=27) from Phase 2 Open Label Extension (OLE) Study Show a Mean 3.1 Point Decrease in Neuropathy Impairment Score (mNIS+7) at 12 Months, ...

press release

May 5, 2017

In Ongoing Phase 1/2 Study, Single Subcutaneous Doses of ALN CC5 Achieve Potent, Statistically Significant, and Highly Durable C5 Knockdown of up to 96% After Single Dose, ALN CC5 Also Achieves up to 92% Inhibition of Serum Complement Activity, Including up to 61% Inhibition of Serum Hemolytic Activity, and was Generally ...